Koasteam, Approval for Clinical Trial Phase 3 Protocol Amendment of Neuronata-RJ
[Asia Economy Reporter Oh Ju-yeon] Corestem announced on the 27th that it has received approval from the Ministry of Food and Drug Safety for changes to the domestic Phase 3 clinical trial plan of Neuronata-AL injection.
The company stated, "We have received approval for changes to the clinical trial plan, including the administration period, efficacy evaluation variables, and the number of subjects."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Controversy Over Mysterious Numbers at Starbucks: From Sewol Ferry and Park Geun-hye to May 18
- Cost Instability Grips 'AI Rally'... Iran War Identified as the Cause
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The target disease is amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
